UPDATE: Wedbush Downgrades Durata Therapeutics as CBST/Hospira Litigation Overhang Looms

In a report published Monday, Wedbush analyst Gregory R. Wade downgraded the rating on Durata Therapeutics (NASDAQ: DRTX ) from Outperform to Neutral, but reiterated the $13.00 price target. In the report, Wedbush noted, “With the stock nearing our $13 price target and the CBST/Hospira Paragraph IV litigation creating a